Status:
UNKNOWN
Administration of Chlorpromazine as a Treatment for COVID-19
Lead Sponsor:
Cairo University
Collaborating Sponsors:
Noha Mahmoud Nasreldin Hassan
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
PHASE3
Brief Summary
In this study, defined cases of COVID-19 confirmed with PCR, with a mild, moderate or severe pneumonia will be treated with chlorpromazine. The improvement in clinical \& laboratory manifestations wil...
Detailed Description
Introduction The COVID-19 pandemic has resulted in over 6 million confirmed infected cases worldwide and over 397,000 deaths as of June 8th, 2020 according to the World Health Organization. Currently,...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Adult conscious male and female (non-pregnant, non-breast feeder), level of consciousness is assessed by Glasgow Coma Scale ≥ 13.
- Diagnosed initially with COVID-19 confirmed with PCR prior to any interference.
- Follow the treatment regimen for COVID-19 according to The Ministry of Health in Egypt.
- Exclusion criteria:
- Patients having allergy to chlorpromazine which will be assessed by asking the patient or relative.
- Patients with hypotension(\<90/60mmHg).
- Pregnant and breast feeder female patients.
- Hepatic patients.
- Patients already receiving chlorpromazine.
Exclusion
Key Trial Info
Start Date :
August 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2020
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04354805
Start Date
August 1 2020
End Date
November 1 2020
Last Update
July 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cairo University
Cairo, Egypt, 11562